TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16414143

Group type: EXPERIMENTAL
Intervention: Amlodipine and ramipril added to previous antihypertensive treatment for 12 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Moderate SBP controlled group (n = 10)
Number of subjects: 21
Study: 14505816

Group type: EXPERIMENTAL
Intervention: Food restriction (FR)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Increased physical activity (EX)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Food restriction (FR) and increased physical activity (EX)
Number of subjects: 13
Study: 11020618

Group type: EXPERIMENTAL
Intervention: Intacs implantation
Number of subjects: 359

Group type: COMPARATOR
Intervention: Control (untreated fellow eyes)
Number of subjects: 359
Study: 8866086

Group type: EXPERIMENTAL
Intervention: Bifurcated expanded polytetrafluoroethylene graft (group I)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Collagen‐impregnated knitted Dacron graft (group II)
Number of subjects: 16
Study: 1740491

Group type: EXPERIMENTAL
Intervention: RU 486 (1 mg/day, orally) for 5 or 15 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progesterone (5-10 mg/day, im, for 2 days) added after RU 486
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10268816

Group type: EXPERIMENTAL
Intervention: Modeling plus rehearsal (treatment group)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Pamphlets addressing breast cancer and BSE (comparison group)
Number of subjects: 292
Study: 31318460

Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: T-DM1+pertuzumab
Number of subjects: 1095

Group type: COMPARATOR
Intervention: HT (trastuzumab plus taxane)
Number of subjects: 1095

Group type: COMPARATOR
Intervention: HT
Number of subjects: 1095
Study: 29241520

Group type: EXPERIMENTAL
Intervention: Dementia-specific training program for nurses using a mobile phone applet, details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care training for older people with disability (control group).
Number of subjects: 0
Study: 25543068

Group type: EXPERIMENTAL
Intervention: dV-Trainer
Number of subjects: 20

Group type: COMPARATOR
Intervention: da Vinci robot
Number of subjects: 20
Study: 24323667

Group type: EXPERIMENTAL
Intervention: GORE(®) Septal Occluder (GSO)
Number of subjects: 60
Study: 23052610

Group type: EXPERIMENTAL
Intervention: Pandemic influenza A/H1N1 vaccine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 92
Study: 19968580

Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg dutasteride
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 5.0 mg/kg dutasteride
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 0.5 mg dutasteride daily for 2‐4 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (regular diet for rats)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no medication for patients)
Number of subjects: 59
Study: 17892991

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES) implantation
Number of subjects: 954

Group type: COMPARATOR
Intervention: Control group (patients younger than 75 years)
Number of subjects: 954
Study: 15383199

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus Lovastatin 20 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lovastatin administration alone
Number of subjects: 18
Study: 11530717

Group type: EXPERIMENTAL
Intervention: Respiratory biofeedback therapy using a handheld capnometry device for 4 weeks
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Physiological monitoring pretherapy and posttherapy
Number of subjects: 4
Study: 9624543

Group type: EXPERIMENTAL
Intervention: Ceftibuten (400 mg od for 5 days)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate (250/125 mg tds for 10 days)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 335

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate
Number of subjects: 335
Study: 7936843

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) 300 U/kg three times a week s.c. and iron at 6 mg/kg/d
Number of subjects: 55

Group type: COMPARATOR
Intervention: Iron at 3 mg/kg/d (control group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) and iron
Number of subjects: 55
Study: 2965827

Group type: COMPARATOR
Intervention: Placebo traction (5 kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Light traction (15 kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Normal traction (50 kg)
Number of subjects: 60
Study: 29198057

Group type: EXPERIMENTAL
Intervention: Individual physical therapy alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined with a high intensity exercise group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (individual physical therapy alone)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (combined with a high intensity exercise group)
Number of subjects: 30
Study: 27068113

Group type: EXPERIMENTAL
Intervention: CARE Plus intervention (including mindfulness-based stress reduction techniques and self-management support)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Training and support for healthcare staff
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Self-management support
Number of subjects: 51
Study: 23633679

Group type: EXPERIMENTAL
Intervention: Selenium 200 µg/d for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 60
Study: 23576623

Group type: EXPERIMENTAL
Intervention: cabergoline (3 mg/day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: levodopa (300 mg/day)
Number of subjects: 35
Study: 20569706

Group type: EXPERIMENTAL
Intervention: PPCI (Primary Percutaneous Coronary Intervention)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: PPCI
Number of subjects: 256
Study: 17526868

Group type: EXPERIMENTAL
Intervention: Nursing intervention model with a gerontologic advanced practice nurse as postacute care coordinator for 6 months (biweekly visits and/or phone calls)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group with care based on postacute facility protocols
Number of subjects: 33
Study: 15310394

Group type: EXPERIMENTAL
Intervention: Interval exercise
Number of subjects: 104

Group type: COMPARATOR
Intervention: High intensity continuous exercise
Number of subjects: 104
Study: 11731181

Group type: EXPERIMENTAL
Intervention: Gelestra (17 beta-estradiol gel 0.6 mg/g)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Estraderm TTS 50 (transdermal delivery system)
Number of subjects: 33
Study: 9717064

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7996377

Group type: EXPERIMENTAL
Intervention: Itraconazole (5 and then 10 mg/kg per day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Historical control group (no prophylaxis)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Historical group (daily ketoconazole prophylaxis)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 32

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 32
Study: 3209324

Group type: EXPERIMENTAL
Intervention: RePUVA therapy (PUVA started with retinoids, gradually increased to 4 j/cm2 by the beginning of the third week)
Number of subjects: 21

Group type: COMPARATOR
Intervention: PUVA only (control group)
Number of subjects: 21
Study: 31959326

Group type: EXPERIMENTAL
Intervention: Active Team (gamified app)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Self-monitoring app
Number of subjects: 444

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 444
Study: 29451945

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Activated Collagen
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 27348253

Group type: EXPERIMENTAL
Intervention: Intensive dietary counseling from pretreatment until 6‐wk posttreatment
Number of subjects: 24
Study: 25687656

Group type: EXPERIMENTAL
Intervention: Mobile-bearing (MB) total knee replacement (TKR)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Fixed-bearing (FB) total knee replacement (TKR)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing (in both MB and FB)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Patellar retention (in both MB and FB)
Number of subjects: 352
Study: 22990217

Group type: EXPERIMENTAL
Intervention: 4-mg nicotine gum
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: 2-mg nicotine gum
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 20102633

Group type: EXPERIMENTAL
Intervention: Iron fortified breakfast cereal (16 mg iron per serve) with two ZESPRI(R) GOLD kiwifruit
Number of subjects: 89

Group type: COMPARATOR
Intervention: Iron fortified breakfast cereal (16 mg iron per serve) with a banana (low ascorbic acid and carotenoid content)
Number of subjects: 89
Study: 18257146

Group type: EXPERIMENTAL
Intervention: 40 mg/day DRI
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: 60 mg/day DRI
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 16679344

Group type: EXPERIMENTAL
Intervention: Telephone screening
Number of subjects: 469

Group type: COMPARATOR
Intervention: Clinic screening
Number of subjects: 469
Study: 14575726

Group type: EXPERIMENTAL
Intervention: TNF-alpha mRNA expression in anorectic patients at admission (mean BMI 14.8 +/- 1.3)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: IL-6 mRNA expression in anorectic patients at admission (mean BMI 14.8 +/- 1.3)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: TNF-alpha mRNA expression during follow-up in formerly anorectic patients (mean BMI 18.7 +/- 0.5)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: IL-6 mRNA expression during follow-up in formerly anorectic patients (mean BMI 18.7 +/- 0.5)
Number of subjects: 11
Study: 11515638

Group type: EXPERIMENTAL
Intervention: Oral health education programme administered by schoolteachers
Number of subjects: 965

Group type: COMPARATOR
Intervention: Control group (schools not having attended the workshop)
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Experimental group (schools that attended the workshop)
Number of subjects: 965

Group type: COMPARATOR
Intervention: Experimental and control schools
Number of subjects: 965
Study: 9950019

Group type: EXPERIMENTAL
Intervention: Transparent film dressings
Number of subjects: 0

Group type: COMPARATOR
Intervention: No dressings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dry sterile gauze dressings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 0
Study: 7811604

Group type: EXPERIMENTAL
Intervention: Curriculum for skin cancer prevention education
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study: 2899102

Group type: EXPERIMENTAL
Intervention: Cetirizine 2 HCl, 10 mg once a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31774849

Group type: EXPERIMENTAL
Intervention: HbA1c change during the first 6 years after diagnosis
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Increase in HbA1c during the first 6 years
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Change in HbA1c
Number of subjects: 494
Study: 30234740

Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (initiated after day 7)
Number of subjects: 1231

Group type: COMPARATOR
Intervention: Early parenteral nutrition (initiated within 24 hours)
Number of subjects: 1231

Group type: EXPERIMENTAL
Intervention: High day 1 plasma concentrations of gamma‐glutamyl transpeptidase, alanine aminotransferase, and aspartate aminotransferase
Number of subjects: 1231

Group type: EXPERIMENTAL
Intervention: Day 1 plasma bilirubin concentrations
Number of subjects: 1231
Study: 26581785

Group type: EXPERIMENTAL
Intervention: Simulation with team-based learning (TBL)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Simulation alone
Number of subjects: 74
Study: 24329856

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: COMPARATOR
Intervention: PEG‐IFN2a
Number of subjects: 68
Study: 22497988

Group type: EXPERIMENTAL
Intervention: 80Hz NMES of 4-second duration to floor of mouth muscles, time-locked to 60 volitional saliva swallows.
Number of subjects: 20
Study: 19934445

Group type: EXPERIMENTAL
Intervention: VR memory training (VRMT) for 6 months, including 3 auditory and 3 VR sessions every 2 weeks for the first 3 months, followed by 1 auditory and 1 VR session per week for the next 3 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Face‐to‐face training sessions using music therapy
Number of subjects: 36
Study: 18277828

Group type: EXPERIMENTAL
Intervention: Supervised 12-week exercise program
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 19
Study: 16136768

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg once daily for 4 weeks
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 12041711

Group type: EXPERIMENTAL
Intervention: AD/HD children (N = 10)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Children with Hyperkinetic Disorder (N = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-AD/HD controls (N = 10)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Controls (N = 12)
Number of subjects: 22
Study: 9917116

Group type: EXPERIMENTAL
Intervention: Lovastatin 10 mg/d, titrated to 20 mg/d and 40 mg/d at 8 and 16 weeks, respectively.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 7743786

Group type: COMPARATOR
Intervention: Imipramine drug therapy (Drug)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interpersonal therapy (IPT‐M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of IPT‐M and Drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0

Group type: COMPARATOR
Intervention: IPT‐M alone
Number of subjects: 0
Study: 2344059

Group type: EXPERIMENTAL
Intervention: 1% rectal methohexital (25 mg/kg)
Number of subjects: 85

Group type: COMPARATOR
Intervention: 10% rectal methohexital (25 mg/kg)
Number of subjects: 85
Study: 7423163

Group type: EXPERIMENTAL
Intervention: CYT alone
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: CYT + FU
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: CYT + GEST
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Responders (CR + PR + NC)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Non-responders
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: All treated patients
Number of subjects: 89
Study: 30936043

Group type: EXPERIMENTAL
Intervention: Mnemonic strategy training (MST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Active education control condition (EP)
Number of subjects: 30
Study: 29622760

Group type: EXPERIMENTAL
Intervention: Supermarket coupon to offset service charge (intervention group)
Number of subjects: 173

Group type: COMPARATOR
Intervention: No financial incentive (control group)
Number of subjects: 173
Study: 28187054

Group type: EXPERIMENTAL
Intervention: 8-week aerobic dance program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 26335078

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate 50 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study: 24131528

Group type: EXPERIMENTAL
Intervention: Automated, interactive cognitive behaviour training (CB training), completed weekly with email reminders.
Number of subjects: 175

Group type: COMPARATOR
Intervention: General health content (control group).
Number of subjects: 175
Study: 20197559

Group type: EXPERIMENTAL
Intervention: Intrathoracic impedance monitoring
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Estimated pulmonary arterial diastolic pressure monitoring
Number of subjects: 16
Study: 17596903

Group type: EXPERIMENTAL
Intervention: Drug court intervention (outpatient treatment with drug court supervision)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Outpatient treatment without drug court supervision
Number of subjects: 287
Study: 16878198

Group type: EXPERIMENTAL
Intervention: Fuji IX (GC Corporation‐‐Japan)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Delton (Dentsply)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Artificial caries process (control)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: No sealing (same treatment as Group II)
Number of subjects: 10
Study: 14526927

Group type: EXPERIMENTAL
Intervention: Uranium gastrointestinal absorption (f1) values
Number of subjects: 50
Study: 10871912

Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy (HRT) and bisphosphonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: HRT alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bisphosphonate alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined HRT and bisphosphonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: HRT group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bisphosphonate group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined HRT and calcitonin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estrogen therapy with testosterone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HRT with monofluorophosphate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of alendronate and parathyroid hormone (PTH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiludronate and PTH, calcitonin and PTH, calcitonin and anabolic steroids
Number of subjects: 0
Study: 9003876

Group type: EXPERIMENTAL
Intervention: Betaxolol (0.5%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Timolol (0.5%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Carteolol (2%)
Number of subjects: 60
Study: 1474172

Group type: EXPERIMENTAL
Intervention: DI‐Antalvic (30 mg dextropropoxyphene and 400 mg paracetamol per capsule, 6 capsules/day for 1 week)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Efferalgan‐Codeine (30 mg codeine and 500 mg paracetamol per tablet, 6 tablets/day for 1 week)
Number of subjects: 141
Study: 6725915

Group type: EXPERIMENTAL
Intervention: Serum cathodic trypsinogen (CT) levels
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Duodenal bicarbonate output
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Enzymatic trypsin output
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Immunoreactive trypsin output
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Serum CT levels
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Enzymatic measurement of duodenal trypsin
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Radioimmunological measurement of duodenal trypsin
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Immunoreactive measurement of trypsin excretion
Number of subjects: 66
Study: 31050672

Group type: COMPARATOR
Intervention: Water intervention
Number of subjects: 7795

Group type: COMPARATOR
Intervention: Sanitation improvements
Number of subjects: 7795

Group type: COMPARATOR
Intervention: Handwashing intervention
Number of subjects: 7795

Group type: COMPARATOR
Intervention: Nutrition intervention
Number of subjects: 7795

Group type: COMPARATOR
Intervention: Combined water+sanitation+handwashing (WSH)
Number of subjects: 7795

Group type: COMPARATOR
Intervention: Nutrition+WSH (N+WSH)
Number of subjects: 7795

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7795
Study: 29130976

Group type: EXPERIMENTAL
Intervention: 8-week ICT training intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 19
Study: 29231298

Group type: EXPERIMENTAL
Intervention: Four-hand-needling therapy (Sanjian (LI 3), Wailaogong (EX‐UE 8), Zhongzhu (TE 3), Houxi (SI 3) on the affected side)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine needling therapy at neck‐Jiaji (EX‐B 2) on bilateral C4, C5 and C6
Number of subjects: 80
Study: 24096683

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy controls (CLcr >90 mL/min)
Number of subjects: 16
Study: 22795636

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Drospirenone
Number of subjects: 171
Study: 19744537

Group type: EXPERIMENTAL
Intervention: G1: hydrofluoric (HF) acid and silane
Number of subjects: 24

Group type: COMPARATOR
Intervention: G2: silane alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: G3: HF acid and silane then dried with warm air (100 degrees C)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: G4: silane alone then dried with warm air (100 degrees C)
Number of subjects: 24
Study: 19020154

Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac 31.5 mg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac 10 mg
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 17162326

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus acidophilus (La1) in yoghurt matrix, 1012 colony-forming units/subject/day for 42 days
Number of subjects: 0
Study: 12798613

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of anti-hepatitis B vaccine (20 microg, doses at 0, 15, and 30 days)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intradermal administration of anti-hepatitis B vaccine (20 microg, doses at 0, 15, and 30 days)
Number of subjects: 66